Vamorolone

Vamorolone
Clinical data
Synonyms VB-15; VBP-15; 16α-Methyl-9,11-dehydroprednisolone; 17α,21-Dihydroxy-16α-methylpregna-1,4,9(11)-triene-3,20-dione
Drug class Corticosteroid; Glucocorticoid
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C22H28O4
Molar mass 356.462 g/mol
3D model (JSmol)

Vamorolone (developmental code names VB-15, VBP-15) is a synthetic glucocorticoid corticosteroid which is under development for the treatment of duchenne muscular dystrophy and a number of other conditions.[1][2][3]

References

  1. http://adisinsight.springer.com/drugs/800035994
  2. Guglieri, M.; Clemens, P.; Cnaan, A.; Damsker, J.; Gordish-Dressman, H.; Morgenroth, L.; Davis, R.; Nagaraju, K.; Hathout, Y.; Athanasiou, D.; Vroom, E.; Bushby, K.; Hoffman, E. (2017). "Vision DMD: A drug development program for vamorolone in Duchenne muscular dystrophy". Neuromuscular Disorders. 27: S17. doi:10.1016/S0960-8966(17)30266-3. ISSN 0960-8966.
  3. Wells E, Kambhampati M, Damsker JM, Gordish-Dressman H, Yadavilli S, Becher OJ, Gittens J, Stampar M, Packer RJ, Nazarian J (2017). "Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor". Oncotarget. 8 (6): 9366–9374. doi:10.18632/oncotarget.14070. PMC 5354737. PMID 28030841.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.